Big pharma snub, lack of placebo to blame for lack of medical pot research: experts

Despite a growing number of Canadians turning to medical cannabis

A disinterested pharmaceutical industry and the conundrum of finding a convincing placebo are just two reasons experts say there has been little quality research into medicinal marijuana.

A growing number of Canadians are turning to medical cannabis despite questions about its risks and effectiveness as a health product.

Marijuana’s unconventional journey onto the medical market puts it at odds with more mainstream medications, which typically undergo years of costly scrutiny before being approved for use, said Mark Ware, a pain researcher at McGill University Health Centre in Montreal.

Ware said pharmaceutical companies are willing to pay hundreds of millions of dollars for clinical trials because once a drug is approved they have a window of time to sell it exclusively.

“When you think about medications that have been given approval to be sold in pharmacies, that’s where most if not all of our medications come from,” he said.

“That model simply does not hold for much of the classical herbal cannabis research, where you’re looking for basic claims of efficacy and safety, but not trying to make a formal claim for a product that is going to be patented.”

READ: Marijuana rules will be ‘a work in progress’

Ware, who also served as vice-chair on the federal government’s task force on legalizing cannabis, said competition among licensed marijuana producers is leading some of them to funnel money toward research in an effort to differentiate their brand from others.

But Dr. Mike Allan, a professor of family medicine at the University of Alberta in Edmonton, said there are few benefits for producers to conduct the research.

“It’s already at market so there’s really no incentive, or virtually no incentive, for licensed producers to take the money they’re generating from the sale of these products and reinvest it in research,” Allan said.

While a positive outcome might not have much of an effect on the industry’s bottom line, a negative outcome could seriously harm profits, he added.

Data from Health Canada show the number of clients registered with licensed medicinal cannabis producers jumped between June 2016 and June 2017, from 75,166 to more than 200,000. Registrations more than tripled in each of the two previous years.

University of Saskatchewan professor, Robert Laprairie, said the absence of the pharmaceutical industry means medical marijuana research is being done for the benefit of the patient.

“We’re in a unique place because a lot of large pharmaceutical companies are reluctant to fund these studies where they don’t necessarily see the incentive for something that they aren’t able to patent,” said Laprairie, who conducts cannabinoid research at the university.

WATCH: Province, Feds see lots of work ahead of marijuana legalization

Laprairie said he has seen a heavy push in recent months from academics, patients and licensed producers for more medical cannabis research.

But Dr. Meldon Kahan of the Women’s College Hospital in Toronto, said this kind of research, sponsored by licensed producers, is still problematic.

“You can design a short-term study with marijuana, or for that matter, with alcohol or opiates, and say, ‘Look, we gave people a bunch of alcohol over a three-day period or one week or one month and they seem to feel better. It helped their anxiety.’ But that doesn’t mean it’s a good medication,” he said.

Kahan said there does appear to be some evidence that cannabidiol, a compound in marijuana, does have some medical benefits, including pain relief, but more study is needed.

Ware said another dilemma in conducting research on medical marijuana is the absence of a plausible placebo, especially because study participants often have experience using cannabis and recognize if they have been placed in the study or control group.

“Access to a credible placebo may seem like an odd thing to have as a challenge,” Ware said.

“But bear in mind that many of these studies are placebo-controlled, so you need a drug which is a credible placebo — looks and smells and for all intents and purposes pretends it is cannabis when in fact it does not have the active ingredient you are testing.”

Allan cited a study that found between 85 and 90 per cent of nurses could tell when patients were on pills derived from cannabis.


@katslepian

katya.slepian@bpdigital.ca

Like us on Facebook and follow us on Twitter.

Just Posted

New Sooke councillors face old issues and new challenges

First meeting of new council sets the stage for the future

Viral video shows Sooke resident calling out illegal crab fishers

The video shows a man and woman with 12 undersized crabs in Sooke

NDP leader Jagmeet Singh and MP Alistair MacGregor weigh in on fishing ban

Singh and MacGregor say improving salmon abundance is important

Feds respond to sexual assault investigation at CFB Esquimalt

Report of Oct. 5 sexual assault on Vancouver Island base taken over by Canadian Forces National Investigation Service

Oak Bay artist celebrates 100 years

Centenarian matriarch credits active artistic lifestyle

People flocking to Vancouver Island city to see hundreds of sea lions

Each year the combination of Steller and California sea lions take over Cowichan Bay

Vancouver Island remembers

Important stories shared as Islanders salute those who made the greatest sacrifice

Greater Victoria Crime Stoppers wanted list for the week of Nov. 14

Greater Victoria Crime Stoppers is seeking the public’s help in locating the… Continue reading

EU divorce deal in peril after two UK Cabinet ministers quit

Negotiators from Britain and the European Union have struck a proposed divorce deal that will be presented to politicians on both sides for approval, officials in London and Brussels said Tuesday.

Northern California fire death toll at 56; 130 missing

Many of the missing are elderly and from Magalia, a forested town of about 11,000 to the north of Paradise.

Canfor to buy 70 per cent stake in Swedish Vida Group for $580 million

The privately held company has nine sawmills in southern Sweden with an annual production capacity of 1.1 billion board feet.

Saudi prosecutor seeks death penalty in Khashoggi’s killing

Saudi Arabia’s top prosecutor is recommending the death penalty for five suspects charged with ordering and carrying out the killing of Saudi writer Jamal Khashoggi.

Mixing business and family: Trudeau turns to Singapore ancestors to widen trade

Trudeau’s ancestor, Esther Bernard, born Farquhar (1796-1838) was the daughter of Major-General William Farquhar (1774-1839), the first British Resident and Commandant of Singapore.

How a group of concerned students inspired Vancouver Island to #TrustYourself

Island Health social media initiative urging survivors of sexual assault to seek medical care

Most Read